Neuronetics, Inc. Common Stock (STIM) is a publicly traded Healthcare sector company. As of May 21, 2026, STIM trades at $1.20 with a market cap of $82.11M and a P/E ratio of -0.85. STIM moved +0.00% today. Year to date, STIM is -15.60%; over the trailing twelve months it is -72.26%. Its 52-week range spans $0.52 to $5.92. Analyst consensus is buy with an average price target of $3.00. Rallies surfaces STIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Neuronetics Board Agrees Valuation Undervalues NeuroStar Platform, Seeks Engagement: Neuronetics’ Board reviewed a public letter from Pointillist Family Office highlighting that current market valuation fails to reflect the strength of its NeuroStar® Advanced Therapy platform. The Board confirmed its commitment to maximizing shareholder value and said it is open to constructive shareholder engagement while executing its long-term strategic priorities.
| Metric | Value |
|---|---|
| Price | $1.20 |
| Market Cap | $82.11M |
| P/E Ratio | -0.85 |
| EPS | $-1.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.92 |
| 52-Week Low | $0.52 |
| Volume | 187.32K |
| Avg Volume | 0 |
| Revenue (TTM) | $74.89M |
| Net Income | $-43.73M |
| Gross Margin | 72.32% |
2 analysts cover STIM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.00.